Pyrazolopyridines as inhibitors of the kinase LRRK2: A patent evaluation (WO2011141756)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 6, 2012, Pages 709-713

  Deng, Xianming ^a,b   Gray, Nathanael S ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Department of Cancer Biology ^*  (United States)

^c XIAMEN UNIVERSITY   (China)

Author keywords

LRRK2 kinase inhibitor; Parkinson's disease; Patent evaluation; Pyrazolopyridine

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[4,3 C]PYRIDIN 3 YL) 1H INDOL 5 OL; 3,4 DISUBSTITUTED 1H PYRAZOLO[4,3 C]PYRIDINE; 4 [3 AMINO 4 (4 (3 FLUOROPHENOXY)PHENYL) 1H PYRAZOLO [4,3 C]PYRIDIN 6 YL]BENZOIC ACID; 4 [3 AMINO 4 (4 (3 FLUOROPHENOXY)PHENYL) 1H PYRAZOLO[ 4,3 C]PYRIDIN 6 YL]BENZOIC ACID; BRUTON TYROSINE KINASE INHIBITOR; LEUCINE RICH REPEAT KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRAZOLOPYRIDINE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; WO2006077319; WO2009114870; WO2010106333; WO2011019780;

ARTICLE; BIOLOGY; BLOOD BRAIN BARRIER; CLINICAL EVALUATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; IC 50; NONHUMAN; PARKINSON DISEASE; PATENT; STILLE REACTION; SUZUKI REACTION;

ANIMALS; ANTIPARKINSON AGENTS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862290090     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.691968     Document Type: Article

References (18)

1. Gandhi PN, Chen SG, Wilson-Delfosse AL.Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.J Neurosci Res 2009;87(6):1283-95
2. Dorsey ER, Constantinescu R, Thompson JP, et al.Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68(5):384-6
3. Daniels V, Baekelandt V, Taymans JM.On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.Neuro-Signals 2011;19(1):1-15
4. Dächsel JC, Farrer MJ.LRRK2 and Parkinson disease.Arch Neurol 2010;67(5):542-7
5. Kumar A, Cookson MR.Role of LRRK2 kinase dysfunction in Parkinson disease.Expert Rev Mol Med 2011;13:e20
6. Kramer T, Lo Monte F, Goring S, et al.Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's Disease models.ACS Chem Neurosci 2012;3(3):151-60
7. Covy JP, Giasson BI.Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2.Biochem Biophys Res Commun 2009;378(3):473-7
8. Lee BD, Shin JH, VanKampen J, et al.Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.Nat Med 2010;16(9):998-1000
9. Ramsden N, Perrin J, Ren Z, et al.Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons.ACS Chem Biol 2011;6(10):1021-8
10. Zhang J, Deng X, Choi HG, et al.Characterization of TAE684 as a potent LRRK2 kinase inhibitor.Bioorg Med Chem Lett 2012;22(5):1864-9
11. Deng X, Dzamko N, Prescott A, et al.Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Nat Chem Biol 2011;7(4):203-5
12. Medical Research Council Technology, UK.Preparation of pyrazolopyridine compounds as kinase inhibitors patent.WO2010106333A1; 2010
13. Medical Research Council Technology, UK.Preparation of pyrazolopyridines as kinase LRRK2 inhibitors for treating and preventing cancer and neurodegenerative diseases.WO2011141756A1; 2011
14. Aventis Pharma S.A., Fr.Preparation of substituted pyrazolopyridines as kinase inhibitors, and their compositions and use for treatment of cancer.WO2006077319A1; 2006
15. Intellikine, Inc., USA.Preparation of pyrazolopyridines as protein and lipid kinase inhibitors.WO2009114870A2; 2009
16. Bristol-Myers Squibb Co., USA.Azaindazoles as Btk kinase modulators and their preparation.WO2011019780A1; 2011
17. Wager TT, Hou X, Verhoest PR, Villalobos A.Moving beyond rules: the development of a Central Nervous System Multiparameter Optimization (CNS MPO) approach to enable alignment of druglike properties.ACS Chem Neurosci 2010;1(6):435-49
18. Chambers JW, Pachori A, Howard S, et al.Small molecule c-jun-N-terminal kinase inhibitors protect dopaminergic neurons in a model of Parkinson's disease.ACS Chem Neurosci 2011;2(4):198-206